Douglas Lauffenburger

Professor

Department
Department of Biological Engineering
Technology Areas
Biomaterials & Bioelectronics: Health Monitoring / Diagnostics: Assays / Drug Discovery and Research Tools: Cell Culture, Cell Interrogation, Genomics & Proteomics, Cell Lines & Organoids / Biotechnology: DNA & RNA Editing / Therapeutics: Small Molecules, Cell Based Therapy, Regenerative Medicine
Impact Areas

Background and Experience

The Lauffenburger research group focuses on elucidating important aspects of receptor-mediated regulation of mammalian blood and tissue cell behavioral functions such as proliferation, adhesion, migration, differentiation, and death. A central paradigm of the group’s work is development and testing of computational models — based on principles from engineering analysis and synthesis — for receptor regulation of cell function by exploiting techniques of molecular biology to alter parameters characterizing receptor or ligand properties in well-characterized cell systems. Quantitative experimental assays are used to measure cell functions, receptor/ligand interaction parameters, and signaling network dynamics. Problems are primarily motivated by health care technologies of interest to pharmaceutical and biotechnological companies, and emphasize multi-disciplinary collaborative interactions, including colleagues in both academia and industry.
Professor Lauffenburger received his B.S. in Chemical Engineering from the University of Illinois and his Ph.D. in Chemical Engineering from the University of Minnesota. Prior to coming to MIT, he was a professor at the University of Illinois and the University of Pennsylvania and a visiting professor at the University of Wisconsin. He has also served as a visiting scientist at the University of Heidelberg, Germany. Professor Lauffenburger was the founding head of the MIT Department of Biological Engineering in 1998 and served as head until 2019.

Technologies

Diminished Proteolytic Shedding of Receptor Tyrosine Kinases Mediates MEK Inhibitor Resistance in Triple-Negative Breast Cancer

Technology / Case number: #16742
Linda Griffith / Madeleine Oudin / Miles Miller / Aaron Meyer / Frank Gertler / Douglas Lauffenburger
Technology Areas: Therapeutics
Impact Areas: Healthy Living
Labels
  • Women's Health
License

Multiplexed Specific Metalloprotease Activity Measurements

Technology / Case number: #19425DE
Steven Robert Tannenbaum / Evan Chiswick / Ravindra Kodihalli / Christi Cook / Caroline Chopko Ahrens / Miles Miller / Douglas Lauffenburger / Linda Griffith
Technology Areas: Biomaterials & Bioelectronics / Diagnostics / Drug Discovery and Research Tools
Impact Areas: Healthy Living
License

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.